Press Releases

Notification from Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB hereby issues a notification that the Company intends to repay its loan to Nexttobe no later than September 30, 2018 according to previously communicated terms for replacement...

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia”) on the 29 November 2017 issued a convertible loan with a total nominal amount of MSEK 28. In total MSEK 9 of the convertible loan have during July, at th...

Status of the Market Authorisation Application of Apealea in the European Union

Oasmia Pharmaceutical AB hereby issues a notification that contrary to what was anticipated in the draft agenda for this month’s meeting by the Committee for Medicinal Products for Human Use (CHMP),...

Status of Orphan designation of Apealea in the European Union

Oasmia Pharmaceutical AB (NASDAQ: OASM) herewith announces that Apealea was designated as an orphan medicine by the European Commission in 2006 and alongside the procedure of the application for asses...

Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 – April 30, 2018

FOURTH QUARTER February 1, 2018 – April 30, 2018
  • Consolidated net sales amounted to TSEK 843 compared to TSEK 44 in the fourth quarter the previous year
  • Operating loss was T...

Results from Oasmia Pharmaceutical’s phase III study have been presented at ASCO annual meeting

During Monday Oasmia Pharmaceutical AB presented the follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer.

Nexttobe Extends Loan to Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company. The cur...

Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced the completed transfer of assets into its wholly owned, US-based...

Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June

Oasmia Pharmaceutical AB announce that follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer will be presented at the 2018 ASCO Annual Meeting in Chicago....

Notification from Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (publ) hereby notify that the Company, Arwidsro Investment and MGC Capital have agreed to extend the payment of the loan, which was communicated January 2nd  until...